Gastric Cancer Global Clinical Trials Review, H1, 2016

GlobalData
1350 Pages - GLDATA54474
$2,500.00

Summary

GlobalData's clinical trial report, “Gastric Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Companies Mentioned

F. Hoffmann-La Roche Ltd.
Sanofi
AstraZeneca Plc
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Novartis AG
Eli Lilly and Company
Bristol-Myers Squibb Company
GlaxoSmithKline Plc
Amgen Inc.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Gastric Cancer Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Gastric Cancer 29
Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting 29
Apr 19, 2016: Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody 29
Apr 18, 2016: Halozyme Expands Oncology Pipeline With PEG-ADA2 Compound Designed For Activity In The Tumor Microenvironment 30
Mar 30, 2016: Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel 30
Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue 31
Mar 16, 2016: Five Prime Therapeutics to Present New Pre-Clinical Data on FPA144 at the 2016 AACR Annual Meeting 31
Feb 23, 2016: Aslan Pharmaceuticals To Present New Data On Varlitinib At Annual American Association For Cancer Research Meeting 32
Clinical Trial Profile Snapshots 33
Appendix 1347
Abbreviations 1347
Definitions 1347
Research Methodology 1348
Secondary Research 1348
About GlobalData 1349
Contact Us 1349
Disclaimer 1349
Source 1350

List of Tables
Gastric Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 6
Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Gastric Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Gastric Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Gastric Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 1348

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports